Drug giant AstraZeneca has invested two billion US dollars (£1.5 billion) in US pharmaceutical firm Summit Therapeutics as part of a cancer treatment research joint venture.
London-listed Astra’s equity investment will help speed up development of Summit’s experimental drug, called ivonescimab, which aims to attack cancer cells and stop them growing by targeting specific proteins.
